{"id":"placebo-plb-injectable","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nocebo effects (adverse events attributed to expectation)"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo contains no active pharmaceutical ingredient and serves as a negative control in randomized controlled trials. By comparing patient outcomes between placebo and active drug groups, researchers can isolate the true therapeutic effect of the investigational agent from natural disease progression and psychological expectation effects. Placebo is essential for establishing statistical significance and regulatory approval of new drugs.","oneSentence":"Placebo is an inert injectable formulation used as a control comparator in clinical trials to establish the efficacy of investigational therapeutics through blinded comparison.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:24.416Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control arm (indication-dependent on parent study)"}]},"trialDetails":[{"nctId":"NCT06233799","phase":"PHASE3","title":"Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2024-07-01","conditions":"Methamphetamine-dependence, Methamphetamine Abuse","enrollment":360},{"nctId":"NCT05262270","phase":"PHASE2","title":"Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Cocaine Use Disorder","enrollment":427},{"nctId":"NCT01402492","phase":"PHASE2, PHASE3","title":"Cocaine Use Reduction With Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-09","conditions":"Cocaine Dependence","enrollment":302},{"nctId":"NCT03078075","phase":"PHASE3","title":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-05-05","conditions":"Methamphetamine Use Disorder","enrollment":403}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Injectable matching (to Naltrexone) placebo","Arm: Placebo Comparator - matched Placebo (PLB)"],"phase":"phase_3","status":"active","brandName":"Placebo (PLB) Injectable","genericName":"Placebo (PLB) Injectable","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is an inert injectable formulation used as a control comparator in clinical trials to establish the efficacy of investigational therapeutics through blinded comparison. Used for Clinical trial control arm (indication-dependent on parent study).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}